person · Reporting owner
Oosthuizen Johannes Jacobus
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | EVP, Oncology & Int?l | May 05, 2026 | May 07, 2026 |
| Vylor Inc.VYLR · Entity 183857 | Director | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2029-05-05 | Direct | 10,605 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 10,605 · Balance 10,605 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.15 · Expires 2036-05-04 | Direct | 31,044 |
Reported balance
After 2026-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-05 · Grant · Acquired 31,044 · Balance 31,044 F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Common StockSEC Table I · non-derivative | Direct | 21,895.389 |
Reported balance
Holding disclosure · report date 2026-05-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 21,895.389 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
Vylor Inc.
Report date October 01, 2026 · Filed October 05, 2026
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed May 7, 2026 15:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 31,044 | $0.00 Strike: $113.15 | $0.00 |
DisclosureSEC source: 0000310158-26-000121 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · EVP, Oncology & Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,044 Underlying: Common Stock · 31,044 shares Expires 2036-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 05, 2026 Filed May 7, 2026 15:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 10,605 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000121 · form4.xml · derivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · EVP, Oncology & Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,605 Underlying: Common Stock · 10,605 shares Expires 2029-05-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,377 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000078 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · EVP, Oncology & Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,755 Underlying: Common Stock · 1,377 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 679 | $110.03 | $74,710.37 |
DisclosureSEC source: 0000310158-26-000078 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · EVP, Oncology & Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,895.389 Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,377 | $110.03 | $151,511.31 |
DisclosureSEC source: 0000310158-26-000078 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · EVP, Oncology & Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,574.389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 21:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 15,000 | $121.87 | $1,827,991.50 |
DisclosureSEC source: 0000310158-26-000040 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,197.389 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.8200 to $121.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 5,026 | $107.40 | $539,792.40 |
DisclosureSEC source: 0000310158-26-000020 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,197.389 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 18,807 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013043 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,807 Underlying: Common Stock · 18,807 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 4,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013043 · form4.xml · derivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,132 Underlying: Common Stock · 4,132 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 8,500 | $84.09 | $714,744.60 |
DisclosureSEC source: 0001127602-25-005928 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,705.474 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.0700 to $84.1000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 08, 2025 Filed Feb 11, 2025 19:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 13,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004103 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,002 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in one installment on 2/8/2025. The Reporting Person's Form 3 filed on 3/10/2022 incorrectly reported that these restricted units vested and were to be distributed in three equal installments on 2/8/2023, 2/8/2024, and 2/8/2025. Read SEC document |
| February 08, 2025 Filed Feb 11, 2025 19:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 6,404 | $87.28 | $558,941.12 |
DisclosureSEC source: 0001127602-25-004103 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,205.474 Read SEC document |
| February 08, 2025 Filed Feb 11, 2025 19:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 13,002 | $87.28 | $1,134,814.56 |
DisclosureSEC source: 0001127602-25-004103 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,609.474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:23 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 8,664 | $97.94 | $848,552.16 |
DisclosureSEC source: 0001127602-25-002351 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,607.474 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/22. Performance shares were paid out at 169 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2024. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2024 Filed May 6, 2024 20:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 912 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014263 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 912 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2024 Filed May 6, 2024 20:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 450 | $127.51 | $57,379.50 |
DisclosureSEC source: 0001127602-24-014263 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,820.949 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2024 Filed May 6, 2024 20:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 912 | $127.51 | $116,289.12 |
DisclosureSEC source: 0001127602-24-014263 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,270.949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 20,508 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013953 · form4.xml · derivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,508 Underlying: Common Stock · 20,508 shares Expires 2034-04-29 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,119 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-24-003352 · form4.xml · derivative · entry 7 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 7,119 shares Expires 2032-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,045 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0001127602-24-003352 · form4.xml · derivative · entry 6 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,049 Underlying: Common Stock · 7,045 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,773 | $0.00 Strike: $75.36 | $0.00 |
DisclosureSEC source: 0001127602-24-003352 · form4.xml · derivative · entry 5 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,773 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 18,959 | $127.18 | $2,411,110.83 |
DisclosureSEC source: 0001127602-24-003352 · form4.xml · nonDerivative · entry 4 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,327.345 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 7,119 | $87.10 | $620,064.90 |
DisclosureSEC source: 0001127602-24-003352 · form4.xml · nonDerivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,286.345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 7,045 | $73.73 | $519,427.85 |
DisclosureSEC source: 0001127602-24-003352 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,167.345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 6,773 | $75.36 | $510,413.28 |
DisclosureSEC source: 0001127602-24-003352 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,122.345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,133 | $119.43 | $374,174.19 |
DisclosureSEC source: 0001127602-24-002036 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,349.345 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/21. Performance shares were paid out at 161 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2023. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 12:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 2,081 | $102.38 | $213,061.31 |
DisclosureSEC source: 0001127602-23-027135 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,190.657 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 30, 2023 Filed Oct 31, 2023 15:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 915 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-026390 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 915 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2021, 10/30/2022 and 10/30/2023. Read SEC document |
| October 30, 2023 Filed Oct 31, 2023 15:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 451 | $102.82 | $46,371.82 |
DisclosureSEC source: 0001127602-23-026390 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,271.657 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 30, 2023 Filed Oct 31, 2023 15:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 915 | $102.82 | $94,080.30 |
DisclosureSEC source: 0001127602-23-026390 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,722.657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 907 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014755 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912 Underlying: Common Stock · 907 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 447 | $118.22 | $52,844.34 |
DisclosureSEC source: 0001127602-23-014755 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,759.748 Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 907 | $118.22 | $107,225.54 |
DisclosureSEC source: 0001127602-23-014755 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,206.748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 20,747 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014557 · form4.xml · derivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,747 Underlying: Common Stock · 20,747 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014222 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 427 | $115.47 | $49,305.69 |
DisclosureSEC source: 0001127602-23-014222 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,299.748 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 866 | $115.47 | $99,997.02 |
DisclosureSEC source: 0001127602-23-014222 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,726.748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 2,091 | $109.88 | $229,759.08 |
DisclosureSEC source: 0001127602-23-002257 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,821.881 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 1,795 | $103.21 | $185,261.95 |
DisclosureSEC source: 0001127602-22-025307 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,730.881 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,045 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · derivative · entry 9 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,094 Underlying: Common Stock · 7,045 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options become exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,540 | $0.00 Strike: $75.36 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · derivative · entry 8 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,773 Underlying: Common Stock · 13,540 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options become exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,455 | $0.00 Strike: $77.62 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · derivative · entry 7 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,455 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options became exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,703 | $0.00 Strike: $62.07 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · derivative · entry 6 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,703 shares Expires 2027-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable in three equal installments on 5/5/2018, 5/5/2019, and 5/5/2020. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 45,561 | $99.47 | $4,531,980.01 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 5 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,525.881 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.3700 to $99.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 7,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 4 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,086.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 13,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,041.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 17,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,501.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 14,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,046.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2022 Filed Nov 1, 2022 20:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 913 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024599 · form4.xml · derivative · entry 4 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915 Underlying: Common Stock · 913 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2021, 10/30/2022 and 10/30/2023. Read SEC document |
| October 30, 2022 Filed Nov 1, 2022 20:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 450 | $100.77 | $45,346.50 |
DisclosureSEC source: 0001127602-22-024599 · form4.xml · nonDerivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,343.881 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.